The antihypertensive actions of statins: Modulation by salt intake

American Journal of Hypertension

Volumn 25, Issue 11, 2012, Pages 1140-1148

  Juncos, Luis I ^a   Juncos, Luis A ^b   García, Nestor H ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; chronic renal failure; high cholesterol; hypertension; salt sensitive hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; NITRIC OXIDE; PLACEBO; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN;

ACCIDENT PREVENTION; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DAHL SALT SENSITIVE RAT; EXPERIMENTAL MODEL; HIGH SODIUM INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SAMPLE SIZE; SODIUM EXCRETION; SPONTANEOUSLY HYPERTENSIVE RAT; ZUCKER RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; OXIDATIVE STRESS; SODIUM; SODIUM CHLORIDE, DIETARY;

EID: 84867747547     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.105     Document Type: Article

References (84)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16:1407-1414.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
6. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274-1275.
7. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:1814-1821.
8. Leu HB, Wu CC, Wu TC, Lin SJ, Chen JW. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. J Formos Med Assoc 2004; 103:914-920.
9. Di Napoli P, Taccardi AA, Grilli A, De Lutiis MA, Barsotti A, Felaco M, De Caterina R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005; 66:462-471.
10. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33:234-241.
11. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hyper-cholesterolemic men. Circulation 1999; 100:2131-2134.
12. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107:106-112.
13. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59:646-654.
14. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295: F53-F59.
15. Gomes ME, Tack CJ, Verheugt FW, Smits P, Lenders JW. Sympathoinhibition by atorvastatin in hypertensive patients. Circ J 2010; 74:2622-2626.
16. Järvisalo MJ, Toikka JO, Vasankari T, Mikkola J, Viikari JS, Hartiala JJ, Raitakari OT. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999; 147:237-242.
17. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, März W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111:2356-2363.
18. Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, Holm T, Andreassen AK, Kjekshus JK. Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clin Cardiol 2004; 27:199-203.
19. Budzyn K, Marley PD, Sobey CG. Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice. Am J Physiol Regul Integr Comp Physiol 2004; 287:R342-R348.
20. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001; 14:1096-1098.
21. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13:3S-10S.
22. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, Valentini M, Tessari F, Ambrosioni E. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24:837-843.
23. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Grassi G, Giannattasio C, Sega R. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45:1072-1077.
24. Mann JI, Lewis B, Shepherd J, Winder AF, Fenster S, Rose L, Morgan B. Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain. Br Med J (Clin Res Ed) 1988; 296:1702-1706.
25. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 352:1801-1807.
26. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med 1986; 15:254-273.
27. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyorälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsene T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 2004; 97:1019-1030.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
29. O'Donnell M P, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992; 20:651-658.
30. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30:968-974.
31. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457.
32. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001; 104:576-581.
33. Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, Mertens A, Smith G, Herregods MC, Holvoet P, Balligand JL. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 2008; 29:128-137.
34. Régrigny O, Atkinson J, Capdeville-Atkinson C, Limiñana P, Chillon JM. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats. Hypertension 2000; 35:1105-1110.
35. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci 2005; 108:349-355.
36. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998; 31:225-231.
37. Gross V, Schneider W, Schunck WH, Mervaala E, Luft FC. Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycorticosterone acetate-salt hypertensive mice. J Am Soc Nephrol 1999; 10:1430-1439.
38. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995; 75:582-586.
39. Delbosc S, Cristol J P, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40:142-147.
40. Park JK, Müller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schäfer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney Int 2000; 58:1420-1430.
41. Rodríguez-Calvo R, Barroso E, Serrano L, Coll T, Sánchez RM, Merlos M, Palomer X, Laguna JC, Vázquez-Carrera M. Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A. Hepatology 2009; 49:106-115.
42. Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 2009; 338:301-309.
43. Pelat M, Dessy C, Massion P, Desager J P, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation 2003; 107:2480-2486.
44. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 2001; 89:415-421.
45. Nadaud S, Dupuis M, Brocheriou I, Haloui M, Louedec L, Capron F, Michel JB, Soubrier F. Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol 2009; 51:253-261.
46. Bae EH, Kim IJ, Park JW, Ma SK, Lee JU, Kim SW. Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats. Nephrol Dial Transplant 2010; 25:1051-1059.
47. Vieira JM Jr, Rodrigues LT, Mantovani E, Dellê H, Mattar AL, Malheiros DM, Noronha IL, Fujihara CK, Zatz R. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol 2005; 101:p82-p91.
48. Hartner A, Klanke B, Cordasic N, Amann K, Schmieder RE, Veelken R, Hilgers KF. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension. J Hypertens 2009; 27:376-385.
49. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
50. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95:473-478.
51. Ferrier KE, Muhlmann MH, Baguet J P, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39:1020-1025.
52. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99:354-360.
53. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211-216.
54. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35:549-555.
55. Ikeda T, Sakurai J, Nakayama D, Takahashi Y, Matsuo K, Shibuya Y, Gomi T, Moriya H, Kobayashi S. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17:502-506.
56. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia P P, Collatina S, Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34:1281-1286.
57. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148:285-292.
58. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003; 63:360-364.
59. Goode GK, Miller J P, Heagerty AM. Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995; 345:362-364.
60. Huang DY, Boini KM, Osswald H, Friedrich B, Artunc F, Ullrich S, Rajamanickam J, Palmada M, Wulff P, Kuhl D, Vallon V, Lang F. Resistance of mice lacking the serum-and glucocorticoid-inducible kinase SGK1 against salt-sensitive hypertension induced by a high-fat diet. Am J Physiol Renal Physiol 2006; 291:F1264-F1273.
61. Wendt N, Schulz A, Qadri F, Bolbrinker J, Kossmehl P, Winkler K, Stoll M, Vetter R, Kreutz R. Genetic analysis of salt-sensitive hypertension in Dahl rats reveals a link between cardiac fibrosis and high cholesterol. Cardiovasc Res 2009; 81:618-626.
62. Egan BM, Weder AB, Petrin J, Hoffman RG. Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men. Relationship to salt-sensitivity status. Am J Hypertens 1991; 4:416-421.
63. Fiore MC, Jimenez PM, Cremonezzi D, Juncos LI, García NH. Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake. Am J Physiol Renal Physiol 2011; 301:F263-F270.
64. Boegehold MA. Effect of dietary salt on arteriolar nitric oxide in striated muscle of normotensive rats. Am J Physiol 1993; 264:H1810-H1816.
65. Banday AA, Muhammad AB, Fazili FR, Lokhandwala M. Mechanisms of oxidative stress-induced increase in salt sensitivity and development of hypertension in Sprague-Dawley rats. Hypertension 2007; 49:664-671.
66. Li J, White J, Guo L, Zhao X, Wang J, Smart EJ, Li XA. Salt inactivates endothelial nitric oxide synthase in endothelial cells. J Nutr 2009; 139:447-451.
67. Zhu J, Mori T, Huang T, Lombard JH. Effect of high-salt diet on NO release and superoxide production in rat aorta. Am J Physiol Heart Circ Physiol 2004; 286:H575-H583.
68. Juncos LI, Martin FL, Baigorria ST, Pasqualini ME, Fiore MC, Eynard AR, Juncos LA, García NH. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency. Nutrition http://dx.doi. org/10.1016/j.nut.2012.02.008, epub ahead of print 12 June 2012.
69. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 1998; 13:1967-1974.
70. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475-481.
71. Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists. Hypertension 1988; 11:I229-I232.
72. Kang CS, Chang NC, Chang ST, Lin CC, Lee TM. Effect of pravastatin on nephroprotection in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2009; 27:2232-2243.
73. Spósito AC, Mansur A P, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83:1497-9, A8.
74. Abetel G, Poget PN, Bonnabry J P. [Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study]. Schweiz Med Wochenschr 1998; 128:272-277.
75. Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005; 46: 310-315.
76. Kanbay M, Yildirir A, Bozbas H, Ulus T, Bilgi M, Muderrisoglu H, Akcay A, Ozdemir FN. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005; 27:297-303.
77. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, Kim DS, Shin EK. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45:1088-1093.
78. Bak AA, Huizer J, Leijten PA, Rila H, Grobbee DE. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. J Intern Med 1998; 244:371-378.
79. Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20:1891-1895.
80. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721-727.
81. Williams B, Lacy PS, Cruickshank JK, Collier D, Hughes AD, Stanton A, Thom S, Thurston H. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009; 119:53-61.
82. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio F P. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792-798.
83. Mancia G, Parati G, Revera M, Bilo G, Giuliano A, Veglia F, Crepaldi G, Zanchetti A. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ 2010; 340:c1197.
84. Tonelli M, Sacks F, Pfeffer M, Lopez-Jimenez F, Jhangri GS, Curhan G. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens 2006; 20:560-565.